Stimcell Energetics is an early-stage biotechnology company developing the eBalance system, a microcurrent electrical therapy device designed to treat symptoms associated with diabetes, including neuropathic pain, high blood pressure, and blood glucose control. The company originally developed two product lines: the eBalance Pro for healthcare practitioners in clinical settings, and the eBalance Home for direct consumer use. Stimcell does not generate meaningful commercial revenue following the cancellation of its Health Canada medical device licenses and the withdrawal of its U.S. FDA application. To bypass regulated medical device approval pathways, Stimcell shifted its strategy to reposition the technology as a general consumer wellness product. The company is working with ADM Tronics Unlimited to redesign the home unit into a smaller, more affordable consumer wellness device targeted for release in early 2026. Stimcell intends to sell these devices directly to consumers and healthcare providers while generating recurring subscription revenue, relying entirely on independent consultants and third-party contractors for product development.